OAM
DNTH icon

Oxford Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Oxford Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-630
Closed -$103K – 1809
2019
Q3 		$103K Buy
+630
New +$120K ﹤0.01% 1629
2019
Q1 		– Sell
-1,403
Closed -$128K – 1728
2018
Q4 		$128K Buy
+1,403
New +$191K ﹤0.01% 1620

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Oxford Asset Management's DNTH Position: Q4 2019 in Review

Oxford Asset Management sold out of Dianthus Therapeutics (DNTH) in Q4 2019, closing a stake of 630 shares — an estimated $103K sold.

Oxford Asset Management first reported a position in DNTH in Q4 2018 and held it in 2 quarters. The position peaked at $128K in Q4 2018. 74 funds tracked by Wall St. Rank hold DNTH as of Q4 2019.

  • Oxford Asset Management reported no remaining Dianthus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Oxford Asset Management sold 630 Dianthus Therapeutics shares in Q4 2019, an estimated $103K.
  • Oxford Asset Management first reported a position in Dianthus Therapeutics in Q4 2018 and held it in 2 quarters.
  • Oxford Asset Management's Dianthus Therapeutics position peaked at $128K in Q4 2018.
  • 74 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.